{"name":"MELINTA THERAP","slug":"melinta-therap","ticker":"","exchange":"","domain":"melintatherap.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2014-01-01","label":"Orbactiv first approved","drug":"Orbactiv","drugSlug":"oritavancin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Orbactiv","genericName":"ORITAVANCIN","slug":"oritavancin","indication":"Bacterial infection of skin","status":"marketed"},{"name":"Orbactiv","genericName":"Orbactiv","slug":"orbactiv","indication":"Bacterial infection of skin","status":"marketed"},{"name":"Single-Dose IV Oritavancin Diphosphate","genericName":"Single-Dose IV Oritavancin Diphosphate","slug":"single-dose-iv-oritavancin-diphosphate","indication":"Acute bacterial skin and skin structure infections (ABSSSI)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Kimyrsa","genericName":"Kimyrsa","slug":"kimyrsa","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"CEM-101","genericName":"CEM-101","slug":"cem-101","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Orbactiv","genericName":"ORITAVANCIN","slug":"oritavancin","phase":"marketed","mechanism":"Orbactiv works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death.","indications":["Bacterial infection of skin","Staphylococcal infection of skin","Streptococcal infection of skin"],"catalyst":""},{"name":"Kimyrsa","genericName":"Kimyrsa","slug":"kimyrsa","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CEM-101","genericName":"CEM-101","slug":"cem-101","phase":"phase_2","mechanism":"CEM-101 is a potent and selective inhibitor of the histone deacetylase 6 (HDAC6) enzyme.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Orbactiv","genericName":"Orbactiv","slug":"orbactiv","phase":"marketed","mechanism":"Small molecule","indications":["Bacterial infection of skin","Staphylococcal infection of skin","Streptococcal infection of skin"],"catalyst":""},{"name":"Single-Dose IV Oritavancin Diphosphate","genericName":"Single-Dose IV Oritavancin Diphosphate","slug":"single-dose-iv-oritavancin-diphosphate","phase":"phase_3","mechanism":"Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria.","indications":["Acute bacterial skin and skin structure infections (ABSSSI)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"marketed":3,"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}